AMOEBA (EPA:AMEBA) - AMOEBA COMMUNICATES ABOUT EUROPEAN WORKING GROUP HELD ON ITS REGULATORY DOSSIER

Transparency directive : regulatory news

11/09/2017 17:40

PRESS RELEASE

AMOEBA COMMUNICATES ABOUT EUROPEAN WORKING GROUP HELD ON ITS REGULATORY
DOSSIER

Lyon (France), September 11th, 2017 - AMOEBA (FR0011051598 - AMEBA), producer
of a biological biocide capable of eliminating bacterial risk in water and
wound care applications, communicates today that the Working Group on
Microorganisms met on September 8th, 2017 at the European Chemicals Agency
(ECHA) headquarters in Helsinki.

AMOEBA, represented by Fabrice PLASSON (Chief Executive Officer) and
accompanied by an expert on amoeba-microorganisms' interactions, took part in
this meeting. During this 6-hour session, AMOEBA had the complete and entire
opportunity to share its views on all points of the dossier.

This Working Group meeting, forming part of the regulatory dossier peer review
by the Member States, represents a major step in the evaluation of the BIOMEBA
biocidal product active substance, Willaertia magna C2c Maky.

The Working Group has confirmed its willingness to close the evaluation of the
active substance during the December 2017 ECHA Biocidal Products Committee
session.

"This newly created expert Working Group, that met for the very first time,
allowed us to intensively and pragmatically share our views on each technical
and scientific aspect of our biological technology." stated Fabrice PLASSON,
Chief Executive Officer of AMOEBA.

About AMOEBA:

AMOEBA group's objective is to become the global leader in eliminating
waterborne bacterial risk in water treatment and wound care applications. Our
solutions represent alternatives to chemical products widely used in the
cooling water treatment and the wound care market. In a global market for
chemical biocides estimated to be worth EUR 21 bn(1) AMOEBA is focusing on the
industrial cooling tower application estimated at EUR 1.7 bn(2). Similarly, in
a global wound care market estimated at EUR 15.2bn(3), AMOEBA is targeting the
chronic wound care market in the USA, estimated to be worth EUR 751 million(4).
The use of Willaertia magna C2c Maky in health care products will be subject to
FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological
biocide for water treatment, BIOMEBA, has not yet been granted marketing
authorization in the USA, Europe and Canada. AMOEBA is taking the required
regulatory steps to be granted marketing authorization in those regions for the
use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France),
AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and
joined the CAC(r) Small index on 21st September 2015. More information on
www.amoeba-biocide.com.

(1): Sources combined by Amoéba from water treatment agencies, Freedonia,
Eurostat and MarketsandMarkets
(2): Amoéba data combined from the following sources: DRIRE 2013, Eurostat,
ARHIA 2013

Contacts:

Amoéba
Nathalie COMBROUSSE
Marketing Communication Manager
Tel. : +33 (0)4 81 09 18 15
nathalie.combrousse@amoeba-biocide.com

Actifin

Ghislaine GASPARETTO
Financial Communication
Tel. : +33 (0)1 56 88 11 11
ggasparetto@actifin.fr

source : webdisclosure.com

AMOEBA's latest news

07/10/2024 17:45

AMOEBA (EPA:AMEBA) - AMOEBA COMMUNICATES ABOUT EUROPEAN WORKING GROUP HELD ON ITS REGULATORY DOSSIER

Transparency directive : regulatory news

AMOEBA's latest news

Other stories